NASDAQ:SPRY ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis $17.88 -0.12 (-0.67%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ARS Pharmaceuticals Stock (NASDAQ:SPRY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARS Pharmaceuticals alerts:Sign Up Key Stats Today's Range$17.70▼$18.1650-Day Range$12.10▼$18.3552-Week Range$8.91▼$18.90Volume1.03 million shsAverage Volume1.51 million shsMarket Capitalization$1.76 billionP/E RatioN/ADividend YieldN/APrice Target$31.00Consensus RatingBuy Company Overview ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. Read More ARS Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreSPRY MarketRank™: ARS Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 384th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageARS Pharmaceuticals has received no research coverage in the past 90 days.Read more about ARS Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($0.55) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ARS Pharmaceuticals is -112.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ARS Pharmaceuticals is -112.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioARS Pharmaceuticals has a P/B Ratio of 6.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ARS Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.42% of the float of ARS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverARS Pharmaceuticals has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in ARS Pharmaceuticals has recently decreased by 4.76%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldARS Pharmaceuticals does not currently pay a dividend.Dividend GrowthARS Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted28.42% of the float of ARS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverARS Pharmaceuticals has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in ARS Pharmaceuticals has recently decreased by 4.76%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment0.95 News SentimentARS Pharmaceuticals has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ARS Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for SPRY on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows2 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ARS Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,024,863.00 in company stock.Percentage Held by Insiders33.50% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ARS Pharmaceuticals' insider trading history. Receive SPRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRY Stock News HeadlinesARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $254,850.00 in StockJuly 4, 2025 | insidertrades.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder James E. Flynn Sells 740,149 SharesJuly 2, 2025 | insidertrades.comA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.July 24 at 2:00 AM | American Alternative (Ad)EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)July 18, 2025 | globenewswire.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $31.00 Consensus Price Target from BrokeragesJuly 14, 2025 | americanbankingnews.comARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle EpinephrineJuly 10, 2025 | seekingalpha.comARS Pharmaceuticals: 'Betting On The Come'July 9, 2025 | seekingalpha.comJim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”June 15, 2025 | msn.comSee More Headlines SPRY Stock Analysis - Frequently Asked Questions How have SPRY shares performed this year? ARS Pharmaceuticals' stock was trading at $10.55 on January 1st, 2025. Since then, SPRY shares have increased by 70.9% and is now trading at $18.03. How were ARS Pharmaceuticals' earnings last quarter? ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.35) EPS for the quarter, hitting analysts' consensus estimates of ($0.35). The firm earned $7.97 million during the quarter, compared to analysts' expectations of $7.48 million. ARS Pharmaceuticals had a negative trailing twelve-month return on equity of 6.94% and a negative net margin of 16.11%. Read the conference call transcript. Who are ARS Pharmaceuticals' major shareholders? Top institutional investors of ARS Pharmaceuticals include Janney Montgomery Scott LLC (0.60%), Knights of Columbus Asset Advisors LLC (0.07%), Harbour Capital Advisors LLC (0.06%) and Matisse Capital (0.06%). Insiders that own company stock include Ra Capital Management, LP, Richard E Lowenthal, Sarina Tanimoto, Laura Shawver, Justin Chakma, Alexander A Fitzpatrick, Eric Karas, Kathleen D Scott, Brian Dorsey, Peter A Thompson and Brent L Saunders. View institutional ownership trends. How do I buy shares of ARS Pharmaceuticals? Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ARS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARS Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/14/2025Today7/24/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SPRY CIK1671858 Webars-pharma.com Phone206-456-2900FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for ARS Pharmaceuticals$31.00 High Price Target$40.00 Low Price Target$27.00 Potential Upside/Downside+72.2%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$8 million Net Margins-16.11% Pretax Margin-15.82% Return on Equity-6.94% Return on Assets-5.60% Debt Debt-to-Equity Ratio0.30 Current Ratio11.00 Quick Ratio10.74 Sales & Book Value Annual Sales$89.15 million Price / Sales19.83 Cash Flow$0.01 per share Price / Cash Flow2,077.16 Book Value$2.64 per share Price / Book6.82Miscellaneous Outstanding Shares98,210,000Free Float65,312,000Market Cap$1.77 billion OptionableOptionable Beta0.90 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:SPRY) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.